Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.39) by 61.14 percent. This is a 65.12 percent increase over losses of $(0.43) per share from the same period last year. The company reported quarterly sales of $23.19 million which beat the analyst consensus estimate of $10.80 million by 114.76 percent. This is a 394.01 percent increase over sales of $4.70 million the same period last year.